Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: Effectiveness and mood conversion rate

British Journal of Psychiatry

Volumn 208, Issue 4, 2016, Pages 359-365

  Amsterdam, Jay D ^a   Lorenzo Luaces, Lorenzo ^a,b   Soeller, Irene ^a   Li, Susan Qing ^a   Mao, Jun J ^a   De Rubeis, Robert J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; TRAZODONE; VENLAFAXINE; ZOLPIDEM; ANTIDEPRESSANT AGENT; LITHIUM DERIVATIVE;

ADULT; AGED; AGITATION; ARTICLE; BIPOLAR II DISORDER; CHRONOTHERAPY; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPOMANIA; INSOMNIA; LITHIUM BLOOD LEVEL; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MAXIMUM PERMISSIBLE DOSE; MAXIMUM TOLERATED DOSE; MENTAL PATIENT; MONOTHERAPY; MOOD CHANGE; NAUSEA; NERVOUSNESS; PARALLEL DESIGN; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; SITTING; STANDING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; ADOLESCENT; BIPOLAR DISORDER; COMPARATIVE STUDY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; VENLAFAXINE HYDROCHLORIDE; YOUNG ADULT;

EID: 84963527097     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.115.169375     Document Type: Article

References (32)

1. Bond DJ, Noronha MM, Kauer-Sant'Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry 2008; 69: 1589-601.
2. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord 2005; 86: 1-10.
3. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A & Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 52: 1130-8.
4. Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 2001; 62: 565-9.
5. Ghaemi SN, Klara JR, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004; 161: 163-5.
6. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-9.
7. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356: 1711-22.
8. Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar type II disorder - a randomized, double-blind, placebo-substitution trial. Am J Psychiatry 2010; 167: 792-800.
9. Amsterdam, JD, Shults, J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. Low mood conversion rate during initial fluoxetine monotherapy of bipolar type II major depressive episode. J Clin Psychopharmacol 2010; 30: 306-11.
10. Amsterdam JD, Luo L, Shults J. Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar type II disorder. Br J Psychiatry 2013; 202: 301-6.
11. Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy of bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol 2008; 28: 171-81.
12. Amsterdam JD, Wang C-H, Schwarz M, Shults J. Initial therapy of rapid and non-rapid cycling patients with bipolar II major depressive episode. J Affect Disord 2009; 112: 219-30.
13. Amsterdam JD, Wang G, Shults J. Venlafaxine monotherapy of bipolar II major depressive episode in non-responders to prior lithium monotherapy: a cross-over study. Acta Psychiatrica Scand 2010; 121: 201-8.
14. Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for bipolar II disorder: a proof of concept study. J Affect Disord 2006; 92: 205-14.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR). APA, 2000.
16. Williams JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiat 1988; 45: 742-7.
17. First MB, Spitzer RL, Gibbon M, Williams JBW Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-I/P W/PSY SCREEN). Biometrics Research, New York State Psychiatric Institute, 2001.
18. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-35.
19. Nivoli AMA, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, González-Pinto A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affective Disord 2011; 129: 14-26.
20. Guy W. ECDEU Assessment Manual for Psychopharmacology. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976.
21. National Institute of Mental Health. TESS (Treatment Emergent Symptom Scale-Write-In). Psychopharmacol Bull 1985; 21: 1069-72.
22. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013; 170: 1249-62.
23. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-9.
24. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356: 1711-22.
25. Kupfer DJ, Chengappa KNR, Gelenberg AJ, Hirschfeld RMA, Goldberg JF, Sachs GS, et al. Citalopram as adjunctive therapy in bipolar depression. J Clin Psychiatry 2001; 62: 985-90.
26. Vieta E, Martinez-Arán A, Manuel Goikolea J, Torrent C, Colom F, Benabarre A, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63: 508-12.
27. Viktorin A, Lichtenstein P, Thase ME, Larsson H, Lundholm C, Magnusson PKE, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 2014; 10: 1067-73.
28. Kupfer DJ, Carpenter LL, Frank E. Possible role of antidepressants in precipitating mania and hypomania in recurrent depression. Am J Psychiatry 1988; 145: 804-8.
29. Amsterdam JD, Garcia-España F, Schweizer E, Fawcett J, Quitkin FM, Reimherr FW, et al. Fluoxetine and bipolar II major depressive episode. J Clin Psychopharmacol 1998; 18: 435-40.
30. Amsterdam JD, Shults J. Fluoxetine monotherapy for bipolar type II and bipolar NOS major depression - a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 2005; 20: 357-64.
31. Amsterdam JD Efficacy and safety of venlafaxine in bipolar type-II and unipolar major depressive disorder. J Clin Psychopharmacol 1998; 18: 414-7.
32. Parker G, McCraw S. The 'disconnect' between initial judgments of lamotrigine vs. its real-world effectiveness in managing bipolar disorder. A tale with wider ramifications. Acta Psychiatr Scand 2015; 132: 345-54.